Really? I thought that's quite a lot of capital for a "start-up" bio-tech company with a MC of only $30M, and that's not including the assets it has.
There's no doubt if it does go to clinical trial phase 2/3 it will cost them $100M+ to complete it but for a "start-up" $17M it's very good capital I would have thought.
Really? I thought that's quite a lot of capital for a "start-up"...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.55 |
Change
-0.450(3.75%) |
Mkt cap ! $246.2M | |||
| Open | High | Low | Value | Volume |
| $11.57 | $11.81 | $11.52 | $78.26K | 6.713K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 132 | $11.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.65 | 123 | 3 |
View Market Depth
| Last trade - 14.53pm 10/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |